A focused collection of 15 calculators, scores, and clinical references.
Explanation and Clinical Context The SCORE system is a validated clinical tool designed to estimate the ten year risk of fatal cardiovascular events in adults. It was developed from large European cohort datasets and is recommended by several European societies for primary prevention. The SCORE model incorporates age, sex, systolic blood pressure, total cholesterol, and smoking status. These variables are chosen beca
Community ASCVD Screening Yield Calculator: Explanation and Clinical Context This tool estimates the yield and population-level impact of community cardiovascular risk screening followed by statin therapy for primary prevention. Inputs include: average 10-year ASCVD risk among screen-positive individuals, expected LDL-C reduction (mmol/L) with the chosen regimen, treatment uptake, adherence, screen-positivity, and sc
Community Cholesterol Program Impact: Explanation and Clinical Context This calculator estimates the population-level impact of a community cholesterol screening program targeting high-risk individuals. The Absolute Risk Reduction (ARR) is derived from the average 10-year ASCVD risk among screen-positive individuals multiplied by the relative risk reduction (RRR) achievable with statin therapy. The Number Needed to T
Cost-Effectiveness of Statin Therapy by Age/Risk Model: Explanation and Clinical Context This calculator implements a transparent, adjustable cost-effectiveness framework for primary-prevention statin therapy anchored to a patient’s 10-year ASCVD risk and therapy intensity. It estimates absolute risk reduction as baseline risk × RRR and converts events prevented into QALYs. Treatment disutility and excess diabetes ri
Digital Health Adherence Impact Index: Explanation and Clinical Context The Digital Health Adherence Impact Index (DHAII) is a composite metric designed to quantify the expected clinical benefit of adherence to prescribed medications combined with engagement in remote monitoring programs. It is calculated using weighted contributions from medication adherence (typically 60%) and remote monitoring engagement (typicall
: Explanation and Clinical Context Influenza vaccination has a significant role in reducing cardiovascular morbidity and mortality, especially among elderly individuals and those with established cardiovascular disease (CVD). Viral infections, particularly influenza, can precipitate acute coronary syndromes, decompensated heart failure, and arrhythmias through mechanisms of systemic inflammation, endothelial dysfunct
Hypertension Screening ROI Model (Health System): Explanation and Clinical/Economic Context This calculator estimates the financial return from implementing a systematic hypertension screening pathway across a health system. It follows a standard budget-impact/ROI framing: total discounted cost savings from major cardiovascular (CVD) events averted minus the total discounted costs of screening, confirmatory assessmen
Mobile Clinic Detection Probability Index (Rural CAD Screening): Explanation and Clinical Context This index is designed for mobile-clinic settings in rural regions, targeting screening of possible Coronary Artery Disease (CAD) in underserved populations. Using variables readily available in a simple outreach screening environment (age, sex, smoking status, hypertension, diabetes, chest pain symptoms), it estimates t
: Explanation and Clinical Context This tool estimates the 5-year risk of sudden cardiac death based on patient characteristics collected in national SCD registries. It incorporates variables including age, sex, history of myocardial infarction, left ventricular ejection fraction (LVEF), and history of heart failure. The model uses logistic regression to calculate the probability of SCD. Higher predicted percentages
This tool estimates the potential population-level yield and benefit of one-time Lp(a) screening. It uses inputs for population size, expected prevalence above a chosen threshold, baseline 10-year ASCVD risk, the relative risk associated with elevated Lp(a), and assumed therapy uptake and relative risk reduction. Notes: Prevalence of Lp(a) ≥125 nmol/L (≈50 mg/dL) is ~20% in many populations; adjust for your local epi
: Explanation and Clinical Context This estimator quantifies the potential impact of reducing average daily salt consumption on population-level blood pressure and cardiovascular risk. Excessive sodium intake is a major modifiable determinant of hypertension, which in turn is a leading cause of stroke, ischemic heart disease, and chronic kidney disease. Meta-analyses have consistently demonstrated that for every 1 gr
Screening ECG Yield in Primary Care: Explanation and Clinical Context The Screening ECG Yield in Primary Care calculator estimates the Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of routine electrocardiographic (ECG) screening programs based on population disease prevalence and test characteristics (sensitivity and specificity). PPV and NPV are essential for evaluating the clinical yield of sc
Smoking Cessation Cardiac Event Reduction Model: Explanation and Clinical Context Smokers who quit experience a rapid decline in cardiovascular risk within the first few years, with heavy smokers (≥20 pack-years) achieving approximately a 39% lower risk of incident cardiovascular disease by 5 years compared with those who continue to smoke (hazard ratio ~0.61). Risk continues to decline more gradually over the follow
: Explanation and Clinical Context The ABCD2 score estimates early stroke risk after a transient ischemic attack (TIA) based on five clinical variables: age ≥ 60 years (1), blood pressure ≥ 140/90 mmHg (1), clinical features (unilateral weakness 2; speech disturbance without weakness 1), symptom duration (≥ 60 minutes 2; 10–59 minutes 1), and diabetes (1). Total 0–7. Risk stratification: Low (0–3), Moderate (4–5), Hi
: Explanation and Clinical Context The Telemonitoring Cost-Benefit Cardiac Program Model is designed to estimate the financial impact and efficiency of implementing telemonitoring programs for patients with chronic heart failure or post–cardiac hospitalization follow-up. It combines key cost elements — baseline hospitalization cost, expected reduction in readmissions, and telemonitoring program expenses — to produce